Skip to main content
SpringerLink
Log in

Traitements intra-artériels des carcinomes hépatocellulaires : évidence clinique et perspectives à venir

Intraarterial therapies of hepatocellular carcinoma: Clinical evidence and future outlook

  • Mise au Point / Update
  • Published:
Oncologie

Résumé

Les traitements intra-artériels hépatiques comme la chimioembolisation et la radioembolisation ont révolutionné la prise en charge des patients atteints d’un carcinome hépatocellulaire. Ces thérapies permettent non seulement de contrôler localement la maladie mais également de prolonger la survie des patients. L’avantage unique de ces traitements minimalement invasifs est l’administration d’une haute dose agent thérapeutique directement dans les vaisseaux nourriciers de la tumeur. Cette approche sélective préserve le parenchyme hépatique non tumoral et minimise la toxicité systémique. Dans cette revue sont brièvement discutées les données actuelles et perspectives à venir des traitements intra-artériels hépatiques les plus fréquemment utilisés.

Abstract

Intraarterial therapies such as transarterial chemoembolization and radioembolization have revolutionized the management of patients with hepatocellular carcinoma. These therapies achieve not only effective local tumor control but also prolong patient survival. The unique advantage of these minimally invasive treatments consists of the administration of high doses of the antitumor agent directly into the tumor feeding arteries. This selective approach preserves the nontumoral liver parenchyma and limits systemic toxicity. In this paper, we provide a brief overview of current evidence and future perspectives of the most frequently used intraarterial therapies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Références

  1. Ferlay J, Soerjomataram I, Dikshit R, et al (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136:E359–E86

    Article  CAS  PubMed  Google Scholar 

  2. El-Serag HB (2011) Hepatocellular carcinoma. N Engl J Med 365:1118–27

    Article  CAS  PubMed  Google Scholar 

  3. European Association for The Study of The Liver, European Organisation for Research, Treatment of Cancer (2012) EASLEORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 56:908–43

    Article  Google Scholar 

  4. Llovet JM, Bruix J (2003) Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 37:429–42

    Article  CAS  PubMed  Google Scholar 

  5. Lo CM, Ngan H, Tso WK, et al (2002) Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 35:1164–71

    Article  CAS  PubMed  Google Scholar 

  6. Llovet JM, Real MI, Montana X, et al (2002) Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 359:1734–9

    Article  PubMed  Google Scholar 

  7. Chung GE, Lee JH, Kim HY, et al (2011) Transarterial chemoembolization can be safely performed in patients with hepatocellular carcinoma invading the main portal vein and may improve the overall survival. Radiology 258:627–34

    Article  PubMed  Google Scholar 

  8. Georgiades CS, Hong K, D’Angelo M, Geschwind JF (2005) Safety and efficacy of transarterial chemoembolization in patients with unresectable hepatocellular carcinoma and portal vein thrombosis. J Vasc Interv Radiol 16:1653–9

    Article  PubMed  Google Scholar 

  9. Gorodetski B, Chapiro J, Schernthaner R, et al (2017) Advancedstage hepatocellular carcinoma with portal vein thrombosis: conventional versus drug-eluting beads transcatheter arterial chemoembolization. Eur Radiol 27:526–35

    Article  PubMed  Google Scholar 

  10. Zhao Y, Duran R, Chapiro J, et al (2016) Transarterial chemoembolization for the treatment of advanced-stage hepatocellular carcinoma. J Gastrointest Surg 20:2002–9

    Article  PubMed  Google Scholar 

  11. Georgiades C, Geschwind JF, Harrison N, et al (2012) Lack of response after initial chemoembolization for hepatocellular carcinoma: does it predict failure of subsequent treatment? Radiology 265:115–23

    Article  PubMed  PubMed Central  Google Scholar 

  12. Laval-Jeantet M, Tristant H, Guerbet M, et al (1972) A new method of lipiodol hepatography using an intraarterial approach. J Radiol Electrol Med Nucl 53:29–34

    CAS  PubMed  Google Scholar 

  13. Nakamura H, Hashimoto T, Oi H, Sawada S (1989) Transcatheter oily chemoembolization of hepatocellular carcinoma. Radiology 170:783–6

    Article  CAS  PubMed  Google Scholar 

  14. Takayasu K, Arii S, Ikai I, et al (2010) Overall survival after transarterial lipiodol infusion chemotherapy with or without embolization for unresectable hepatocellular carcinoma: propensity score analysis. AJR Am J Roentgenol 194:830–7

    Article  PubMed  Google Scholar 

  15. Raoul JL, Heresbach D, Bretagne JF, et al (1992) Chemoembolization of hepatocellular carcinomas. A study of the biodistribution and pharmacokinetics of doxorubicin. Cancer 70:585–90

    CAS  PubMed  Google Scholar 

  16. Petruzzi NJ, Frangos AJ, Fenkel JM, et al (2013) Single-center comparison of three chemoembolization regimens for hepatocellular carcinoma. J Vasc Interv Radiol 24:266–73

    Article  PubMed  Google Scholar 

  17. Shi M, Lu LG, Fang WQ, et al (2013) Roles played by chemolipiodolization and embolization in chemoembolization for hepatocellular carcinoma: single-blind, randomized trial. J Natl Cancer Inst 105:59–68

    Article  CAS  PubMed  Google Scholar 

  18. Favelier S, Boulin M, Hamza S, et al (2013) Lipiodol transarterial chemoembolization of hepatocellular carcinoma with idarubicin: first experience. Cardiovasc Intervent Radiol 36:1039–46

    Article  PubMed  Google Scholar 

  19. Brown DB, Nikolic B, Covey AM, et al (2012) Quality improvement guidelines for transhepatic arterial chemoembolization, embolization, and chemotherapeutic infusion for hepatic malignancy. J Vasc Interv Radiol 23:287–94

    Article  PubMed  Google Scholar 

  20. Lencioni R, de Baere T, Soulen MC, et al (2016) Lipiodol transarterial chemoembolization for hepatocellular carcinoma: a systematic review of efficacy and safety data. Hepatology 64:106–16

    Article  CAS  PubMed  Google Scholar 

  21. Lencioni R, de Baere T, Burrel M, et al (2012) Transcatheter treatment of hepatocellular carcinoma with doxorubicin-loaded DC Bead (DEBDOX): technical recommendations. Cardiovasc Intervent Radiol 35:980–5

    Article  PubMed  Google Scholar 

  22. Varela M, Real MI, Burrel M, et al (2007) Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol 46:474–81

    Article  CAS  PubMed  Google Scholar 

  23. Lammer J, Malagari K, Vogl T, et al (2010) Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol 33:41–52

    Article  PubMed  Google Scholar 

  24. Golfieri R, Giampalma E, Renzulli M, et al (2014) Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma. Br J Cancer 111:255–64

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Monier A, Guiu B, Duran R, et al (2017) Liver and biliary damages following transarterial chemoembolization of hepatocellular carcinoma: comparison between drug-eluting beads and lipiodol emulsion. Eur Radiol 27:1431–39

    Article  PubMed  Google Scholar 

  26. Schernthaner RE, Haroun RR, Duran R, et al (2016) Improved visibility of metastatic disease in the liver during intra-arterial therapy using delayed arterial phase cone-beam CT. Cardiovasc Intervent Radiol 39:1429–37

    Article  PubMed  PubMed Central  Google Scholar 

  27. Miyayama S, Yamashiro M, Hashimoto M, et al (2013) Identification of small hepatocellular carcinoma and tumor-feeding branches with cone-beam CT guidance technology during transcatheter arterial chemoembolization. J Vasc Interv Radiol 24:501–8

    Article  PubMed  Google Scholar 

  28. Lewis AL, Dreher MR, O’Byrne V, et al (2016) DC BeadM1™: towards an optimal transcatheter hepatic tumour therapy. J Mater Sci Mater Med 27:13

    Article  PubMed  Google Scholar 

  29. Duran R, Sharma K, Dreher MR, et al (2016) A novel inherently radiopaque bead for transarterial embolization to treat liver cancer — a pre-clinical study. Theranostics 6:28–39

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Levy EB, Krishnasamy VP, Lewis AL, et al (2016) First human experience with directly image-able iodinated embolization microbeads. Cardiovasc Intervent Radiol 39:1177–86

    Article  PubMed  Google Scholar 

  31. Bize P, Duran R, Fuchs K, et al (2016) Antitumoral effect of sunitinib-eluting beads in the rabbit VX2 tumor model. Radiology 280:425–35

    Article  PubMed  Google Scholar 

  32. Duran R, Mirpour S, Pekurovsky V, et al (2017) Preclinical benefit of hypoxia-activated intraarterial therapy with evofosfamide in liver cancer. Clin Cancer Res 23:536–48

    Article  CAS  PubMed  Google Scholar 

  33. Duffy AG, Ulahannan SV, Makorova-Rusher O, et al (2017) Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma. J Hepatol 66:545–51

    Article  CAS  PubMed  Google Scholar 

  34. Geschwind JF, Kudo M, Marrero JA, et al (2016) TACE treatment in patients with sorafenib-treated unresectable hepatocellular carcinoma in clinical practice: final analysis of GIDEON. Radiology 279:630–40

    Article  PubMed  Google Scholar 

  35. Lencioni R, Llovet JM, Han G, et al (2016) Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: the SPACE trial. J Hepatol 64:1090–8

    Article  CAS  PubMed  Google Scholar 

  36. University College London (2014) TACE-2 — a randomised placebo-controlled, double blinded, phase III trial evaluating sorafenib in combination with transarterial chemoembolisation (TACE) in patients with unresectable hepatocellular carcinoma (HCC). In: UK Clinical Research Network Study Portfolio [cited 2014 July 1]. Available from: http://public.ukcrn.org.uk/search/StudyDetail.aspx?StudyID=5347. UKCRN ID:5347

    Google Scholar 

  37. Kudo M, Han G, Finn RS, et al (2014) Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: a randomized phase III trial. Hepatology 60:1697–707

    Article  CAS  PubMed  Google Scholar 

  38. Maluccio MA, Covey AM, Porat LB, et al (2008) Transcatheter arterial embolization with only particles for the treatment of unresectable hepatocellular carcinoma. J Vasc Interv Radiol 19:862–9

    Article  PubMed  Google Scholar 

  39. Malagari K, Pomoni M, Kelekis A, et al (2010) Prospective randomized comparison of chemoembolization with doxorubicineluting beads and bland embolization with BeadBlock for hepatocellular carcinoma. Cardiovasc Intervent Radiol 33:541–51

    Article  PubMed  Google Scholar 

  40. Brown KT, Do RK, Gonen M, et al (2016) Randomized trial of hepatic artery embolization for hepatocellular carcinoma using doxorubicin-eluting microspheres compared with embolization with microspheres alone. J Clin Oncol 34:2046–53

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Bruix J, Sherman M, Practice Guidelines Committee AAftSoLD (2005) Management of hepatocellular carcinoma. Hepatology 42:1208–36

    Article  PubMed  Google Scholar 

  42. Denys A, Pracht M, Duran R, et al (2015) How to prepare a patient for transarterial radioembolization? A practical guide. Cardiovasc Intervent Radiol 38:794–805

    Article  PubMed  Google Scholar 

  43. Kulik LM, Carr BI, Mulcahy MF, et al (2008) Safety and efficacy of Y90 radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. Hepatology 47:71–81

    Article  PubMed  Google Scholar 

  44. Salem R, Gordon AC, Mouli S, et al (2016) Y90 Radioembolization significantly prolongs time to progression compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology 151:1155–63e2

    Article  PubMed  Google Scholar 

  45. Salem R, Lewandowski RJ, Kulik L, et al (2011) Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology 140:497–507e2

    Article  PubMed  Google Scholar 

  46. Salem R, Gilbertsen M, Butt Z, et al (2013) Increased quality of life among hepatocellular carcinoma patients treated with radioembolization, compared with chemoembolization. Clin Gastroenterol Hepatol 11:1358–65e1

    Article  PubMed  Google Scholar 

  47. Salem R, Lewandowski RJ, Mulcahy MF, et al (2010) Radioembolization for hepatocellular carcinoma using yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology 138:52–64

    Article  CAS  PubMed  Google Scholar 

  48. Hilgard P, Hamami M, Fouly AE, et al (2010) Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival. Hepatology 52:1741–9

    Article  CAS  PubMed  Google Scholar 

  49. Sangro B, Carpanese L, Cianni R, et al (2011) Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation. Hepatology 54:868–78

    Article  PubMed  Google Scholar 

  50. Salem R, Gordon AC, Mouli S, et al (2016) Y90 Radioembolization significantly prolongs time to progression compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology 151:1155–63 e2

    Article  PubMed  Google Scholar 

  51. Duran R, Deltenre P, Denys A (2017) Re: Y90 radioembolization significantly prolongs time to progression compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology 152:1625–26

    Article  PubMed  Google Scholar 

  52. Edeline J, Lenoir L, Boudjema K, et al (2013) Volumetric changes after (90)y radioembolization for hepatocellular carcinoma in cirrhosis: an option to portal vein embolization in a preoperative setting? Ann Surg Oncol 20:2518–25

    Article  PubMed  Google Scholar 

  53. Garin E, Rolland Y, Edeline J, et al (2015) Personalized dosimetry with intensification using Y90-loaded glass microsphere radioembolization induces prolonged overall survival in hepatocellular carcinoma patients with portal vein thrombosis. J Nucl Med 56:339–46

    Article  CAS  PubMed  Google Scholar 

  54. Llovet JM, Ricci S, Mazzaferro V, et al (2008) Sorafenib in advanced hepatocellular carcinoma. Ne Engl J Med 359:378–90

    Article  CAS  Google Scholar 

  55. Chow PK, Poon DY, Khin MW, et al (2014) Multicenter phase II study of sequential radioembolization-sorafenib therapy for inoperable hepatocellular carcinoma. PLoS One 9:e90909

    Article  PubMed  PubMed Central  Google Scholar 

  56. Gramenzi A, Golfieri R, Mosconi C, et al (2015) Yttrium-90 radioembolization vs sorafenib for intermediate-locally advanced hepatocellular carcinoma: a cohort study with propensity score analysis. Liver Int 35:1036–47

    Article  CAS  PubMed  Google Scholar 

  57. Edeline J, Crouzet L, Campillo-Gimenez B, et al (2016) Selective internal radiation therapy compared with sorafenib for hepatocellular carcinoma with portal vein thrombosis. Eur J Nucl Med Mol Imaging 43:635–43

    Article  CAS  PubMed  Google Scholar 

  58. BTG International Inc. (2000) A Prospective Randomized Clinical Trial on 90yttrium trans-arterial radio-embolization (TheraSphere®) vs. standard of care (sorafenib) for the treatment of advanced hepatocellular carcinoma (HCC) with portal vein thrombosis (PVT). In: ClinicalTrials.gov [Internet]. National Library of Medicine (US), Bethesda (MD) [cited 2014 July 1]. Available from: http://clinicaltrials. gov/show/NCT01887717. NLM Identifier: NCT01887717

    Google Scholar 

  59. Singapore General Hospital (2000) Phase III multi-centre openlabel randomized controlled trial of selective internal radiation therapy (SIRT) versus sorafenib in locally advanced hepatocellular carcinoma (SIRveNIB). In: ClinicalTrials.gov [Internet]. National Library of Medicine (US), Bethesda (MD) [cited 2014 July 1]. Available from: http://clinicaltrials.gov/show/NCT01135056. NLM Identifier: NCT01135056

    Google Scholar 

  60. Assistance publique–Hôpitaux de Paris (2000) Sorafenib versus radioembolization in advanced hepatocellular carcinoma (SARAH). In: ClinicalTrials.gov [Internet]. National Library of Medicine (US), Bethesda (MD) [cited 2014 July 1]. Available from: http://clinicaltrials.gov/show/NCT01482442. NLM Identifier: NCT01482442

    Google Scholar 

  61. University of Magdeburg (2000) Sorafenib and micro-therapy guided by primovist enhanced MRI in patients with inoperable liver cancer (SORAMIC). In: ClinicalTrials.gov [Internet]. National Library of Medicine (US), Bethesda (MD) [cited 2014 July 1]. Available from: http://clinicaltrials.gov/show/NCT01126645. NLM Identifier: NCT01126645

    Google Scholar 

  62. BTG International Inc. (2000) A phase III clinical trial of intraarterial TheraSphere® in the treatment of patients with unresectable hepatocellular carcinoma (STOP-HCC). In: ClinicalTrials.gov [Internet]. National Library of Medicine (US), Bethesda (MD) [cited 2014 July 1]. Available from: http://clinicaltrials.gov/show/ NCT01556490. NLM Identifier: NCT01556490

    Google Scholar 

  63. Burrel M, Reig M, Forner A, et al (2012) Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using drug eluting beads. implications for clinical practice and trial design. J Hepatol 56:1330–5

    Article  PubMed  Google Scholar 

  64. Yau T, Tang VY, Yao TJ, et al (2014) Development of Hong Kong Liver Cancer staging system with treatment stratification for patients with hepatocellular carcinoma. Gastroenterology 146:1691–700 e3

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Diagnostic and Interventional Radiology, Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne, Lausanne, Switzerland

    R. Duran

  2. Department of Radiology and Biomedical Imaging, Yale University School of Medicine, New Haven, CT, USA

    J. -F. Geschwind

Authors
  1. R. Duran
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. -F. Geschwind
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J. -F. Geschwind.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Duran, R., Geschwind, J.F. Traitements intra-artériels des carcinomes hépatocellulaires : évidence clinique et perspectives à venir. Oncologie 19, 158–167 (2017). https://doi.org/10.1007/s10269-017-2711-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10269-017-2711-3

Mots clés

Keywords

Search

Navigation